Kimberly-Clark Corporation (KMB)

NASDAQ: KMB · Real-Time Price · USD
103.09
-0.76 (-0.73%)
At close: Nov 10, 2025, 4:00 PM EST
103.16
+0.07 (0.07%)
After-hours: Nov 10, 2025, 7:48 PM EST
-0.73%
Market Cap34.21B
Revenue (ttm)19.72B
Net Income (ttm)1.97B
Shares Out 331.86M
EPS (ttm)5.91
PE Ratio17.43
Forward PE13.38
Dividend$5.04 (4.85%)
Ex-Dividend DateSep 5, 2025
Volume7,028,633
Open103.81
Previous Close103.85
Day's Range101.61 - 103.87
52-Week Range99.22 - 150.45
Beta0.25
AnalystsHold
Price Target130.45 (+26.54%)
Earnings DateOct 30, 2025

About KMB

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care products in the United States. It operates through three segments: North America, International Personal Care, and International Family Care and Professional. The company North America segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers, and other related produc... [Read more]

Founded 1910
Employees 38,000
Stock Exchange NASDAQ
Ticker Symbol KMB
Full Company Profile

Financial Performance

In 2024, Kimberly-Clark's revenue was $20.06 billion, a decrease of -1.83% compared to the previous year's $20.43 billion. Earnings were $2.55 billion, an increase of 44.27%.

Financial Statements

Analyst Summary

According to 11 analysts, the average rating for KMB stock is "Hold." The 12-month stock price target is $130.45, which is an increase of 26.54% from the latest price.

Price Target
$130.45
(26.54% upside)
Analyst Consensus: Hold
Stock Forecasts

News

I'm Buying Dividend Aristocrats At Bargain Basement Prices

It pays to buy high quality at a discount. In this article, I highlight two attractively valued Dividend Aristocrats. Both are trading well below their normal valuations and carry historically high di...

Other symbols: PEP
18 hours ago - Seeking Alpha

A Look at Earnings for Two Stocks

This issue will look a little different. It will read more like the weekly updates I send to my premium Yield Shark readers.

Other symbols: HTGC
1 day ago - ETF Trends

Watch These Stocks Falling 10% Or More

Fiserv (FI) leads decliners with a 49% drop, driven by leadership turmoil, weak consumer spending, and a downgraded quant rating to 'Strong Sell.' Alexandria Real Estate (ARE) and Robert Half (RHI) su...

6 days ago - Seeking Alpha

Kenvue's $48.7 Billion Sale Puts Consumer Staples ETFs Back In Vogue

Consumer staples ETFs, usually the quiet corner of the market, are suddenly in the spotlight. The $48.7 billion acquisition of Kenvue Inc. (NYSE:KVUE) by Kimberly-Clark Corp (NASDAQ:KMB) has stirred r...

Other symbols: KVUEIYKVDCXLP
6 days ago - Benzinga

3 Dividend Stocks for November 2025

This month's trio includes two ADRs.

Other symbols: DEOGSK
6 days ago - Morningstar

The CEO Behind Kimberly-Clark's $40 Billion Gamble on Tylenol Maker

Mike Hsu aims to stoke the consumer company's growth by veering into Kenvue's higher-margin but risky health products.

Other symbols: KVUE
7 days ago - WSJ

Kimberly-Clark CEO Mike Hsu goes one-on-one with Jim Cramer

Kimberly-Clark Chairman and CEO Mike Hsu joins 'Mad Money' host Jim Cramer to talk the recent acquisition of Kenvue, quarterly results, consumer trends, and more.

7 days ago - CNBC Television

Kenvue Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kenvue Inc. - KVUE

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...

Other symbols: KVUE
7 days ago - Business Wire

Kimberly-Clark CEO talks Kenvue acquisition, calls Tylenol brand 'resilient'

Kimberly-Clark CEO Mike Hsu told CNBC's Jim Cramer that his company's acquisition of Tylenol maker Kenvue will create value for shareholders, even as the the pain reliever is scrutinized by the Trump ...

Other symbols: KVUE
7 days ago - CNBC

Kenvue's legal risks loom over planned acquisition by Kimberly-Clark

Kimberly-Clark said on Monday it plans to acquire Band-Aid maker Kenvue , even as the latter company faces thousands of lawsuits involving its painkiller Tylenol and talc-based baby powder, raising qu...

Other symbols: KVUE
7 days ago - Reuters

S&P 500 Gains & Losses Today: Amazon Stock Jumps After OpenAI Deal; Kimberly-Clark Acquires Kenvue

A linkup with an artificial intelligence player helped power shares of a top cloud-computing services company higher Monday, while an acquisition in the consumer goods space sent the two stocks on div...

Other symbols: AMZNKVUE
7 days ago - Investopedia

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kenvue Inc.

NEW YORK , Nov. 3, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kenvue Inc. (NYSE: KVUE) and its board of directors concerning the proposed acquisition ...

Other symbols: KVUE
7 days ago - PRNewsWire

Kimberly-Clark's $50 billion leap into health and beauty tests investor faith

Kimberly-Clark's nearly $50 billion offer for Tylenol maker Kenvue is a risky bet that the world's biggest consumer market, the United States, will keep growing even as lower-income shoppers trim thei...

Other symbols: KVUE
7 days ago - Reuters

KVUE stock price: Kenvue soars 19% today, Kimberly-Clark deal offers a win after Trump Tylenol drama

It's been a tough few weeks for the consumer health company Kenvue, after President Trump publicly spread unproven claims about Tylenol, one of its core subsidiary brands. Today, though, it seems like...

Other symbols: KVUE
7 days ago - Fast Company

Kimberly-Clark Corporation (KMB) M&A Call Transcript

Kimberly-Clark Corporation ( KMB) M&A Call November 3, 2025 8:00 AM EST Company Participants Christopher Jakubik - Investor Relations Contact Michael Hsu - Chairman & CEO Kirk Perry - Interim CEO & D...

7 days ago - Seeking Alpha

Options Corner: Kimberly-Clark's Implosion Offers An Unusual Informational Arbitrage Opportunity

Kimberly-Clark Corporation (NASDAQ:KMB) rattled its shareholders when it earlier announced its acquisition of consumer goods giant Kenvue Inc (NYSE:KVUE). Ordinarily, such an acquisition might make se...

7 days ago - Benzinga

Explainer: Is Tylenol safe to take during pregnancy?

There is no firm evidence of a link between the use of the drug and autism.

Other symbols: KVUE
7 days ago - Reuters

Top Stock Movers Now: Amazon, Kenvue, Kimberly-Clark, Beyond Meat, and More

Major U.S. equities indexes were mixed Monday afternoon, as tech stocks gained but most other sectors declined. The S&P 500 and Nasdaq rose, while the Dow fell.

Other symbols: AMZN
7 days ago - Investopedia

Kenvue deal could double Kimberly-Clark stock's multiple: find out more

Kenvue Inc (NYSE: KVUE) opened about 20% higher this morning after Kimberly-Clark (NYSE: KMB) announced a $40 billion acquisition of the consumer health company. According to its press release, it wil...

Other symbols: KVUE
7 days ago - Invezz

Kimberly-Clark to buy Tylenol maker Kenvue in massive consumer merger

The deal would bring Huggies, Kleenex, Band-Aid, Neutrogena, and Tylenol under one roof, creating a consumer staples giant. Transcript: Caroline Woods: Big brands and big money - Kimberly-Clark is buy...

Other symbols: KVUE
7 days ago - The Street

Kimberly-Clark Is Buying Tylenol Maker Kenvue for Nearly $49B. Here's What You Need to Know

Kenvue (KVUE) shares skyrocketed in early trading Monday after Kleenex and Cottonelle maker Kimberly-Clark (KMB) said it's buying the Tylenol maker in a $48.7 billion deal.

Other symbols: KVUE
7 days ago - Investopedia

Kimberly-Clark Buying Tylenol Maker Kenvue in $40 Billion Deal

Kimberly-Clark agreed to buy Kenvue in a deal worth roughly $40 billion in a combination that could create a company with $32 billion in revenue and allow it to surpass Unilever to become the second-b...

Other symbols: KVUE
7 days ago - Bloomberg Markets and Finance

Kimberly-Clark buys Tylenol maker Kenvue in a cash and stock deal for $48.7 billion

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.

Other symbols: KVUE
7 days ago - New York Post

Activist Investors in Kenvue Faced Big Losses. Kimberly-Clark Saved the Day.

D.E. Shaw, one of the Tylenol-maker's largest shareholders, stood to lose over $200 million but is now expected to break even on its bet.

Other symbols: KVUE
7 days ago - WSJ

Kimberly-Clark agrees to buy Tylenol owner Kenvue, creating consumer staples giant

Kimberly-Clark announced Monday it's struck an agreement to buy Kenvue in a deal valued at $48.7 billion. CNBC's David Faber breaks down the details.

Other symbols: KVUE
7 days ago - CNBC Television